Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results
Bologna, M.; Vaggi, L.; Flammini, D.; Carlucci, G.; Forchetti, C.M.
Drugs under Experimental and Clinical Research 11(2): 95-100
1985
ISSN/ISBN: 0378-6501 PMID: 3836122 Document Number: 243736
Prostatic infections are difficult both to diagnose and to treat and have negative influences on the fertility of the patient. Norfloxacin, a new quinolone antibacterial agent particularly active in urinary tract infections, gave excellent results (400 mg every 12 h for 10 days) in the treatment of chronic-relapsing prostatitis in a group of 20 patients. An 85% success rate was recorded at the end of a follow-up period of 30 days without any undesired effects. This clinical study was paralleled by a pharmacokinetic evaluation of the serum, urine and prostatic tissue concentrations attained by the drug, measured by an HPLC [high-performance liquid chromatography] assay on biological fluids and tissue extracts from surgical specimens of 15 patients suffering from benign prostatic hypertrophy and given two 400 mg doses of norfloxacin in the 12 h preceding prostatectomy. The average tissue concentrations (1 .mu.g/gm), as compared with the MIC90 [90% minimal inhibitory concentration] of the drug for the pathogens sustaining prostatic infections [Enterococcus, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa], appear quite sufficient to control the bacterial foci responsible for the chronic-relapsing course of prostatitis and easily account for the clinical success rate.